Anvisa warns of risk of pancreatitis and reinforces that slimming pens require prescription and medical monitoring.

In an interview with the CB.Poder program of Correio Brasiliense, conducted by journalists Adriana Bernardes and Sibele Negromonte, Leandro Safatle, acting CEO of Anvisa, detailed the behind-the-scenes and expectations regarding the new regulation of medicinal cannabis and research in Brazil

Correction published in the Official Gazette clarifies requirements on packaging and maintains authorization for magistral manipulation of CBD

Resolution No. 1,015/2026 tightens technical requirements, expands sanitary controls, and consolidates authorization as a transitional step before the registration of medicines

New RDC No. 1,011 expands regulatory details on Cannabis derivatives, medicinal products, and pharmaceutical inputs

Despite technical feasibility, Anvisa conditions the production of cannabidiol on the publication of a specific regulation, with validity in 90 days

Agency defines a modular strategy for cannabis cultivation, establishing distinct rules for patient associations, research, and industry

Revision of RDC 327 allows the compounding sector to produce derivatives, while individual importation by individuals remains under old rules and will be analyzed separately

Anvisa's proposal establishes a new regulatory framework for industrialized medicinal cannabis products in Brazil

Anvisa directors meet this Wednesday (28) to discuss the update of medicinal cannabis regulations; learn how to follow

Anvisa directors meet this Wednesday (28) to discuss the update of medicinal cannabis regulations; learn how to follow

Proposal authorizes companies to cultivate plants with up to 0.3% THC exclusively for the production of medicinal inputs, but experts warn of the technical unfeasibility of the limit in a tropical climate

New resolution allows planting by universities and pharmaceutical industries, requiring maximum security systems and total traceability of the plant

Proposal aims to regulate the performance of non-profit entities in a controlled experimental environment, using the Regulatory Sandbox model to comply with STJ decision

Norm review may limit imports via RDC 660 if there is a national equivalent; director Thiago Campos presents dissenting vote

The National Narcotics Fund (FNE) will no longer require Export Certificates for shipments destined to patients (Individuals) in Brazil, eliminating a bureaucratic obstacle that hindered the flow of derivatives between the two countries

Adesaf Institute points out unconstitutionality in vetoing workers with criminal history in research areas and requests review of measure

Marcelo Mario Matos Moreira takes over as substitute in the Fourth Board, filling the vacancy of the former rapporteur of the review of RDC 327

Rômison Rodrigues Mota leaves the position after a request for review delays the norm's vote; the topic will return to the regulatory agenda for 2026-2027

New regulation simplifies registration and expands the use of biodiversity in herbal medicines, as soon as cannabis products are classified as medicines, they must comply with these standards.